Navigation Links
Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific

LONDON, July 11, 2014 /PRNewswire/ --

On Thursday, July 10, 2014, the NASDAQ Composite ended at 4,396.20, down 0.52%, the Dow Jones Industrial Average finished the day 0.42% lower at 16,915.07, and the S&P 500 closed at 1,964.68, down 0.41%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 711.88, down 0.02%, while the index has advanced 2.75% in the last one month. Investor-Edge has initiated coverage on the following equities: Covidien PLC (NYSE: COV), Baxter International Inc. (NYSE: BAX), DexCom Inc. (NASDAQ: DXCM) and Boston Scientific Corp. (NYSE: BSX). Free technical research on COV, BAX, DXCM and BSX can be downloaded upon signing up at:

On Thursday, Covidien PLC's stock recorded a trading volume of 3.65 million shares, lower than its three months average volume of 4.42 million shares. The stock finished the day at $91.00, up 0.10%, and registered an intraday range of $89.90 and $91.25. Covidien PLC's shares have rallied 24.69% in the last one month and 29.65% in the previous three months. Also, the stock has advanced 33.63% on YTD basis. Furthermore, the company's stock is trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $78.29 is above its 200-day moving average of $70.23. Additionally, shares of the company traded at a PE ratio of 24.73 and have a Relative Strength Index (RSI) of 75.19. Sign up today to read free research on COV at:

Baxter International Inc.'s stock gained 1.23%, to close Thursday's session at $76.75, after hitting a new 52-week high of $76.78. The stock recorded a trading volume of 3.31 million shares, above its three months average volume of 2.60 million shares. Over the last one month and previous three months, Baxter International Inc.'s shares have surged 4.08% and 6.21%, respectively. Also, from the beginning of 2014, the company's stock has gained 10.35%. The stock is trading above its 50-day and 200-day moving averages. The company stock's 50-day moving average of $74.12 is above its 200-day moving average of $69.85. Further, the company's stock traded at a PE ratio of 15.82 and has an RSI of 66.00. Sign up today to read free research on BAX at:

On Thursday, DexCom Inc.'s stock finished the session 0.66% lower at $35.93. A total of 0.42 million shares were traded, which was below its three months average volume of 0.90 million shares. The stock moved between $34.67 and $36.39 during the session. Over the last one month and past three months, DexCom Inc.'s shares have lost 3.10% and 0.33%, respectively. However, the stock has gone up 1.47% since the start of this year. The company's shares are trading above their 50-day and 200-day moving averages. Moreover, the stock's 200-day moving average of $35.89 is greater than its 50-day moving average of $35.32. DexCom Inc.'s stock has an RSI of 41.43. Sign up today to read free research on DXCM at:

Shares in Boston Scientific Corp. fluctuated between $12.83 and $13.10 before ending Thursday's session up 0.61%, at an intra-day high of $13.10. The company's stock reported a trading volume of 10.08 million shares, below its three months average volume of 12.56 million shares. Further, shares of Boston Scientific Corp. have advanced 0.61% over the past three trading sessions and 2.02% over the last one month. Also, the stock has surged 8.99% on YTD basis. The stock is trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $12.84 is greater than its 200-day moving average of $12.62. Moreover, shares of the company traded at a PE ratio of 28.86 and have an RSI of 55.62. Sign up today to read free research on BSX at:


1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at]

5. For any urgent concerns or inquiries, please contact us at compliance [at]

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] for consideration.

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Nutrilys Del Mar Joins Health Forces With LAPD Underwater Dive Unit
2. Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinsons Disease
3. Netsmarts Focus on Innovation to Help Health and Human Service Providers Span the Spectrum of Care in the Healthcare 3.0 Environment
4. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
5. Attendees Save Up To $800 on Global Healthcare Conferences in 2012 by Registering Through Global Information Inc.
6. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
7. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
8. Genomic Health to Announce First Quarter 2012 Financial Results and Host Conference Call on Wednesday, May 2, 2012
9. Nearly 300 Medical Device, Healthcare Professionals Attend First National Conference on Value-driven Engineering
10. Varian Medical Systems and Siemens Healthcare Announce Global Collaboration to Advance Clinical Capabilities and Offerings in Radiotherapy and Radiosurgery
11. Med Ad News Honors Healthcare Communication Agencies at 23rd Annual Manny Awards
Post Your Comments:
(Date:11/26/2015)... , Nov. 26, 2015 Research and ... of the "2016 Future Horizons and Growth ... Market: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> --> ... of the Italian therapeutic drug monitoring market, including ...
(Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
(Date:11/25/2015)... MINNEAPOLIS , Nov. 25, 2015  ARKRAY ... care products, continues to provide evidence demonstrating the accuracy ... the World Congress on Insulin Resistance, Diabetes and Cardiovascular ... showed that both the Company,s GLUCOCARD ® 01 ... met high accuracy requirements. The ability to accurately measure ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... ... Water For Empowerment ™ attracts volunteers together who want to combine talents ... women as key stakeholders in the process. The non-profit launched its first major ...
(Date:11/25/2015)... ... November 25, 2015 , ... Finnleo, a leader in ... on several models of traditional and far-infrared saunas. , For traditional saunas, ... the most traditional Finnish sauna wood, and Finnleo uses only European Grade A Nordic ...
(Date:11/25/2015)... Cokato, MN (PRWEB) , ... November 25, 2015 ... ... manufacturer, launched offering factory direct sauna parts and accessories. , Sauna accessories ... representative of the bather’s style and personality. From basic styles for the purist ...
(Date:11/25/2015)... ... November 26, 2015 , ... Ministers, ... Union (EU), ANDI Pan African Centres of Excellence, and public R&D institutions, civil ... for the opening of the 5th African Network for Drugs and Diagnostics Innovation, ...
(Date:11/25/2015)... Friendswood, TX (PRWEB) , ... November 25, 2015 , ... ... through the companies’ “ Two Organizations, One Beat ” campaign. The partnership between the ... its services to aid in MAP International’s cause. , MAP International was founded in ...
Breaking Medicine News(10 mins):